Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329368 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer
A Phase 1 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00329368: Completed Phase 1 study, sponsored by Endocyte.
NCT00329368 is a Phase 1 study that has completed, run by Endocyte. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00329368, a Phase 1 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase 1b clinical trial to assess the safety and tolerability of vaccination with EC90 (KLH-FITC) and GPI-0100 (adjuvant) followed by treatment with EC17 (Folate-FITC) in combination with low-dose cytokines (IL-2 and IFN-alpha) in patients with metastatic or refractory cancer.
Interventions
- DRUG Interleukin-2
- DRUG Interferon-alpha
- BIOLOGICAL EC90 (KLH-FITC)
- BIOLOGICAL GPI-0100
- DRUG EC17 (Folate-FITC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329368
The ClinicalTrials.gov registry entry for NCT00329368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Interleukin-2 is the first listed.
NCT00329368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329368 about?
NCT00329368 is a clinical study titled "Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer". This is a Phase 1b clinical trial to assess the safety and tolerability of vaccination with EC90 (KLH-FITC) and GPI-0100 (adjuvant) followed by treatment with EC17 (Folate-FITC) in combination with low-dose cytokines (IL-2 and IFN-alpha) in patients with metastatic or refractory cancer.
What is the current status of trial NCT00329368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2005-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00329368?
The interventions under investigation include: Interleukin-2 (DRUG), Interferon-alpha (DRUG), EC90 (KLH-FITC) (BIOLOGICAL), GPI-0100 (BIOLOGICAL), EC17 (Folate-FITC) (DRUG).
Who is sponsoring clinical trial NCT00329368?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.